New ophthalmic diagnostic technologies are advancing care, particularly when they work in synergy with new treatment paradigms.
This market will be buoyed by increasing ophthalmic surgical procedures worldwide and fear of cross-contamination, but growth in some segments will be constrained by greater use of micro-surgical techniques.
Many of the NHS’s PCTs have raised the visual acuity threshold for cataract surgery in an effort to control costs, denying or delaying surgery for thousands of UK residents.
The FDA granted few regulatory approvals to ophthalmic devices during the past eight months. Review times increased nearly 60 percent from 2005 to 2010.
Generics and labeling changes have dominated FDA regulatory approvals for ophthalmic drugs thus far in 2011, but many await the likely approval of Eylea (VEGF Trap-Eye) later this year.
This month's news includes the latest from Transcend Medical, SARcode Bioscience, Ivantis, MicroLabs and Bausch & Lomb.
You are not currently logged in.
©2017 Market Scope
Lost your Password